Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Sponsor: Celltrion
Summary
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
Official title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone Co-administration in Patients With Type II Diabetes With Insufficient Glycemic Control With Metformin and Empagliflozin Combination Therapy
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
606
Start Date
2024-08-27
Completion Date
2026-05-04
Last Updated
2026-05-15
Healthy Volunteers
No
Conditions
Interventions
CT-L03 Group 1
tablets, QD, oral administration
CT-L03 Group 2
tablets, QD, oral administration
Placebo
tablets, QD, oral administration
Empagliflozin
tablet, QD, oral administration
Metformin
tablets, oral administration
Locations (1)
Celltrion
Incheon, South Korea